Off-label thrombolysis is not associated with poor outcome in patients with stroke

Stroke

Volumn 41, Issue 7, 2010, Pages 1450-1458

  Meretoja, Atte ^a   Putaala, Jukka ^a   Tatlisumak, Turgut ^a   Atula, Sari ^a   Artto, Ville ^a   Curtze, Sami ^a   Häppölä, Olli ^a   Lindsberg, Perttu J ^b   Mustanoja, Satu ^a   Piironen, Katja ^a   Pitkäniemi, Janne ^c   Rantanen, Kirsi ^a   Sairanen, Tiina ^a   Salonen, Oili ^a   Silvennoinen, Heli ^a   Soinne, Lauri ^a   Strbian, Daniel ^a   Tiainen, Marjaana ^a   Kaste, Markku ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Biomedicum Helsinki   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

acute stroke; cerebral infarct; contraindications; ICH; off label; thrombolysis; thrombolytic Rx; tPA

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANTICOAGULATION; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE; BRAIN HEMORRHAGE; BRAIN INFARCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; STATISTICAL MODEL; STROKE; THROMBOCYTE COUNT; TREATMENT OUTCOME; ADOLESCENT; AGE; FOLLOW UP; MIDDLE AGED; REGISTER; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OFF-LABEL USE; REGISTRIES; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954176107     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.576140     Document Type: Article

References (25)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
3. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
4. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;3:CD000213.
5. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
6. Meretoja A, Tatlisumak T. Thrombolytic therapy in acute ischemic stroke\basic concepts. Curr Vasc Pharmacol. 2006;4:31-44.
7. Meretoja A, Tatlisumak T. Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke? CNS Drugs. 2008;22: 619-629.
8. Schumacher HC, Bateman BT, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, Pile-Spellman J. Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004. Ann Emerg Med. 2007;50:99-107.
9. Boode B, Welzen V, Franke C, van Oostenbrugge R. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis. 2007;23:294-298.
10. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med. 2006;31:S210-S216.
11. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
12. Lindsberg PJ, Soinne L, Tatlisumak T, Roine RO, Kallela M, Happola O, Kaste M. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA. 2004;292:1862-1866.
13. Lindsberg PJ, Soinne L, Roine RO, Salonen O, Tatlisumak T, Kallela M, Happola O, Tiainen M, Haapaniemi E, Kuisma M, Kaste M. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke. 2003;34:1443-1449.
14. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007; 369:275-282.
15. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857-872.
16. Toni D, Lorenzano S, Agnelli G, Guidetti D, Orlandi G, Semplicini A, Toso V, Caso V, Malferrari G, Fanucchi S, Bartolomei L, Prencipe M. Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis. 2008;25:129-135.
17. Ringleb PA, Schwark C, Kohrmann M, Kulkens S, Juttler E, Hacke W, Schellinger PD. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry. 2007;78: 690-693.
18. Toni D, Lorenzano S. Intravenous thrombolysis with rt-PA in acute stroke patients aged ≥80 years. Int J Stroke. 2008;4:21-22.
19. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med. 2005;46:243-252.
20. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442-2449.
21. Tsivgoulis G, Frey JL, Flaster M, Sharma VK, Lao AY, Hoover SL, Liu W, Stamboulis E, Alexandrov AW, Malkoff MD, Alexandrov AV. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke. 2009;40:3631-3634.
22. Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, Tilley BC. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998;29:1504-1509.
23. Rost NS, Masrur S, Pervez MA, Viswanathan A, Schwamm LH. Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. Neurology. 2009;73:1957-1962.
24. Aleu A, Mellado P, Lichy C, Kohrmann M, Schellinger PD. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke. 2007;38:417-422.
25. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, Christianson TJ. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35:2418-2424.